# Abalone Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abalone-bio

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.abalonebio.com
- Latest round: Seed (Jan 1, 2020)
- Investors on record: 1

## About

Based in California, US, and founded in 2017, Abalone Bio operates as a biotechnology research company that treats diseases with bioactive antibody drugs which are developed by activating therapeutic biology. The company was Co-founded by Richard Yu (CEO) and Gustavo Pesce. In January 2022, Abalone Bio raised seed funding led by Asymmetry Ventures.

The biotechnology company develops antibody drugs that are used for anti-cancer and anti-inflammatory actions. The firm is working on internal programs which include diabetic peripheral neuropathic pain, immuno-oncology, obesity, and diabetes, which are in the discovery or preclinical stages. It is also working on an Immuno-oncology drug which is a partnered program and it is currently in the discovery stage.

## Funding rounds

- Seed, Jan 1, 2020 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed